Hematology

In Relapsed Chronic Lymphocytic Leukemia Ofatumumab May Extend Linger

Ofatumumab support treatment seems to delay movement free endurance (PFS) in patients with backslid constant lymphocytic leukemia (CLL), as indicated by conclusive outcomes from the PROLONG study (ClinicalTrials.gov Identifier: NCT01039376) distributed in Blood Cancer Journal. Delay was a global, multicenter, open-name, randomized, stage 3 investigation on ofatumumab upkeep in patients with CLL in complete abatement […]